NCT02963051 - A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

December 30, 2018

Study Completion Date

February 1, 2020

Conditions

Prostate Cancer

Interventions

DRUG

Copper

1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15

DRUG

Disulfiram

"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"

DRUG

Copper gluconate

"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"

Trial Locations (1)

Duke University Medical Center, Durham